The sedative effects of a 2 -adrenergic receptor agonists are mediated by receptors located primarily on locus coeruleus neurons in the pons of the lower brainstem (Svensson et al., 1975; Cedarbaum & Aghajanian, 1976) . Brainstem locus coeruleus contains a 2 -adrenergic receptors and microinjection of a 2 -adrenergic receptor agonists into the locus coeruleus produced sedation and analgesia (DeSarro et al., 1987) . The sedative and analgesic properties of these agents have found prominent clinical applications in both veterinary and human medicine.
I NT R OD U C T IO N
The sedative effects of a 2 -adrenergic receptor agonists are mediated by receptors located primarily on locus coeruleus neurons in the pons of the lower brainstem (Svensson et al., 1975; Cedarbaum & Aghajanian, 1976) . Brainstem locus coeruleus contains a 2 -adrenergic receptors and microinjection of a 2 -adrenergic receptor agonists into the locus coeruleus produced sedation and analgesia (DeSarro et al., 1987) . The sedative and analgesic properties of these agents have found prominent clinical applications in both veterinary and human medicine.
Pharmacologically, four subtypes (A, B, C and D) of the a 2 -adrenergic receptor have been reported based primarily on differences in affinity for several drugs (Bylund et al., 1992 (Bylund et al., , 1988 . Genetically, however, there appears to be only three receptor subtypes corresponding to the A, B and C subtypes of a 2 -adrenergic receptor. The a 2D -adrenergic receptor subtype (Rat RG20) (Lanier et al., 1988) as identified in bovine pineal and rat submaxillary glands is considered to be a species homologue of the a 2A -adrenergic receptor (Blaxall et al., 1993) . These two receptors possess &89% sequence homology but differ in their pharmacological properties. The genes for three human a 2 -adrenergic receptors subtypes have been cloned and are designated a 2 -C10, a 2 -C2 and a 2 -C4 and correspond to the A, B and C subtypes, respectively (Bylund et al., 1992) . Homologues in rat and pig have also been cloned (Bylund et al., 1992) . a 2 -Adrenergic receptors are distributed throughout the central nervous system in a non-homogeneous fashion. The a 2A -and a 2C -subtypes predominate throughout the brain (Rosin et al., 1993; MacDonald & Scheinin, 1995) and the a 2B -subtype is reported to be present in the thalamus (Scheinin et al., 1994) . In the rat, the locus coeruleus is abundant in the mRNA coding for the a 2A -adrenergic receptor (Scheinin et al., 1994) and studies using a 2A -adrenergic receptor antisense oligodeoxynucleotides have reported that the hypnotic response to the a 2 -adrenergic receptor agonist dexmedetomidine in the locus coeruleus of the rat is mediated by the a 2A -adrenergic receptor (Mizobe et al., 1996) . a 2 -Adrenergic receptor agonists are widely used in veterinary medicine as sedative/hypnotic agents. Xylazine was the first centrally active a 2 -adrenergic receptor agonist used as an anaesthetic adjunct. More recently, the selective a 2 -adrenergic receptor agonists detomidine and medetomidine have become widely available. To date, no study has systematically examined the pharmacological properties of all three sedative agents on all four a 2 -adrenergic receptor subtypes. Therefore, the aim of this study was to examine the pharmacological properties of the sedative/hypnotic agents xylazine, detomidine and medetomidine at the four a 2 -adrenergic receptor subtypes using tissues Affinity of detomidine, medetomidine and xylazine for alpha-2 adrenergic receptor subtypes Schwartz, D. D., Clark, T. P. Affinity of detomidine, medetomidine and xylazine for alpha-2 adrenergic receptor subtypes. J. vet. Pharmacol. Therap. 21, 107±111. a 2 -Adrenergic receptor agonists are widely used in veterinary medicine as sedative/hypnotic agents. Four pharmacological subtypes of the a 2 -adrenergic receptor (A, B, C and D) have been identified based primarily on differences in affinity for several drugs. The purpose of this study was to examine the affinities of the sedative agents, xylazine, detomidine and medetomidine at the four a 2 -adrenergic receptor subtypes. Saturation and inhibition binding curves were performed in membranes of tissues containing only one subtype of a 2 -adrenergic receptor. The K D for the a 2 -adrenergic receptor radioligand, [
3 H]-MK-912, in HT29 cells (a 2A -), neonatal rat lung (a 2B -), OK cells (a 2C -) and PC12 cells transfected with RG20 (a 2D -) were 0.38 + 0.08 nM, 0.70 + 0.5 nM, 0.07 + 0.02 nM and 0.87 + 0.03 nM, respectively. Detomidine and medetomidine had approximately a 100 fold higher affinity for all the a 2 -adrenergic receptors compared to xylazine but neither agonist displayed selectivity for the a 2 -adrenergic receptor subtypes. These data suggest that available sedative/ hypnotic a 2 -adrenergic receptor agonists can not discriminate between the four known a 2 -adrenergic receptor subtypes. that contain only one subtype of a 2 -adrenergic receptor (HT29, a 2A -; rat neonatal lung, a 2B -; OK cells, a 2C -; PC12 cells transfected with RG20, a 2D -). Northern blot analysis, ribonuclease protection assays and radioligand binding studies have established the existence of only one subtype of a 2 -adrenergic receptor in these tissues (Zeng et al., 1990; Byland et al., 1992; Sun et al., 1992) .
ME THODS

Membrane preparations
Harlan Sprague-Dawley rat pups (1±2 days old) were anaesthetized with Halothane and decapitated. The lungs (containing a 2B -adrenergic receptors) were rapidly removed and snap frozen in liquid nitrogen. Lungs were homogenized in 10 volumes of homogenization buffer (50 mM Tris, 5 mM EDTA, pH 7.4) with a polytron (Kinematica GmbH, Kriens-Luzern, Switzerland) (setting #10, 2 6 30 s). HT-29 cells containing the a 2A -adrenergic receptor (American Type Tissue Culture HTB-38) were grown in McCoy's 5a medium, 90%, foetal bovine serum (FBS), 10%. OK cells containing the a 2C -adrenergic receptor (American opossum proximal tubule, ATCC CRL-1840) were grown in Eagle's MEM with Earle's BSS, 90%; FBS, 10%. PC12 cells transfected with RG20 (a gift from Dr Stephen Lanier, Medical University of South Carolina) were grown in DMEM with high glucose, 90%, FBS 10% (Sato et al., 1995) . Cells were rinsed with phosphate buffered saline, scraped and homogenized in homogenization buffer in a polytron (setting #10, 2 6 30 s). Homogenates from neonatal rat lung, HT-29, OK and PC12 cells were centrifuged at 45 000 6 g, 4 8C, 15 min and washed twice. The final pellet was suspended in homogenization buffer and protein concentration determined with the Bradford method. All procedures involving the use of animals were approved by the institution's animal care and use committee.
Radioligand binding assays
Binding studies were carried out with the a 2 -adrenergic receptor radioligand [
3 H]-MK-912 (76.5 Ci/mmol, New England Nuclear, Boston, MA) (Uhlen et al., 1994) . Saturation experiments were carried out in assay buffer (50 mM Tris, 0.5 mM EGTA (pH 7.4)) containing either 5±10 mg protein (PC12 cells) or 100±200 mg protein (rat lung, HT29 and OK cells) and [ Membranes were incubated for 1 h at 25 8C. The experiment was terminated by rapid dilution of the suspension with ice cold assay buffer followed by vacuum filtration through GF/C filters (Whatman, Clifton, NJ) and washing with 2 6 4 mL assay buffer. Radioactivity on the filters was determined by liquid scintillation counting. 5 nM) and various concentrations of competing drug for 1 h at 25 8C in a volume of 250 mL. The experiment was terminated by rapid dilution of the suspension with ice cold assay buffer followed by vacuum filtration through GF/C filters (Whatman, Clifton, NJ) and washing with 2 6 4 mL assay buffer. Radioactivity on the filters was determined by liquid scintillation counting. The IC 50 values were converted to K i (inhibitor constant) values by the method of Cheng and Prusoff (1973) . (Fig. 1) . Non-specific binding was determined in the presence of RX-821002 (2 mM). (Fig. 2) . The calculated K i values and slope of the Hill plots are depicted in Table 2 . Detomidine and medetomidine had approximately a 100 fold higher affinity for all four subtypes of a 2 -adrenergic receptors compared to xylazine, but neither agonist displayed selectivity between subtypes.
Drugs and chemicals
D I S C US S I ON
Activation of a 2 -adrenergic receptors mediate a wide variety of responses including sedation, analgesia, vasoconstriction and hyperthermia. Pharmacologically, a 2 -adrenergic receptors can be divided into four distinct subtypes of receptors based on the affinities of various drugs (Bylund et al., 1988 (Bylund et al., , 1992 . Physiologically, however, the functional correlates for these subtypes are less clear (MacKinnon et al., 1994) . The purpose of this study was to examine the pharmacological binding properties of three widely used sedatives, xylazine, detomidine and medetomidine at the four subtypes of a 2 -adrenergic receptors in tissues containing only one subtype of receptor. The data suggest that detomidine and medetomidine have a higher affinity for all the a 2 -adrenergic receptors subtypes vs. xylazine, although neither drug showed any selectivity for a particular a 2 -adrenergic receptor subtype. In this study, tissues containing only one a 2 -adrenergic receptor subtype were used for radioligand binding studies. The human adenocarcinoma cell line, HT29, contains the a 2A -adrenergic receptor that is found in human platelets and corresponds to the human a 2 -C10 gene (Bylund et al., 1992) . Neonatal rat lung is a prototype for the a 2B -adrenergic receptor and is analogous to the human a 2 -C2 adrenergic receptor (Bylund et al., 1988 (Bylund et al., , 1992 . The human a 2 -C4 gene codes for the a 2C -adrenergic receptor has pharmacological properties similar to the a 2 -adrenergic receptor found in OK cells (Blaxall et al., 1991) . In the present study, we have also used PC12 cells transfected with the cloned rat homologue of the human a 2 -C10 receptor (RG20) (Lanier et al., 1988) . The human a 2A -adrenergic receptor and the rat a 2D -adrenergic receptor are structurally very similar (Blaxall et al., 1993) , but have different ligand binding properties (Lanier et al., 1988) .
The a 2 -adrenergic receptor radioligand [ 3 H]MK-912 was used in the present study. [ 3 H]MK-912 has been reported to be selective for the a 2C -adrenergic receptor compared to the a 2A -and a 2B -adrenergic receptor (Uhlen et al., 1994) . The present study confirms and extends the former study by examining the affinity of [ for the a 2C -compared to the a 2A -, a 2B -or a 2D -adrenergic receptor (0.38 + 0.08 nM, 0.7 + 0.05 nM, 0.87 + 0.03 nM, respectively), confirming that this radioligand is selective for the a 2C -adrenergic receptor subtype.
#1998 Blackwell Science Ltd, J. vet. Pharmacol. Therap. 21, 107±111 Alpha-2 agonist affinity 109 The affinities of the sedative/analgesics xylazine, detomidine and medetomidine were determined at the four different a 2 -adrenergic receptor subtypes with [ 3 H]MK-912. Xylazine showed low affinity for all four subtypes (range 1200±1460 nM) whereas detomidine and medetomidine displayed much higher affinity (range 3±26 nM). This difference in affinities is reflected in the effective sedative dose of these agents. Detomidine and medetomidine are administered in the mg/kg intravenous (i.v.) dosage range whereas xylazine is administered in the mg/kg i.v. range (Plumb, 1995) . Despite the difference in affinities of xylazine compared to detomidine and medetomidine for the a 2 -adrenergic receptor, there was no selectivity for any of these agents for the different subtypes.
Species differences exist to the clinical response of a 2 -adrenergic receptor agonists. For example, ruminants are extremely sensitive to the sedative and hypotensive effects of xylazine compared to other species (Plumb, 1995) , and this difference cannot be explained by species difference in metabolism and/or excretion (Garcia-Villar et al., 1981; Gross & Booth, 1995) . Data from the present study suggest that differences in the affinity of the a 2 -adrenergic receptor agonists for the various subtypes cannot explain this enhanced sensitivity in ruminants. The subtype of a 2 -adrenergic receptor mediating sedation in the rat is reported to be the A subtype (Mizobe et al., 1996) . Less is known about the subtype mediating sedation in other species. Bovine appear to possess the a 2D -adrenergic receptor subtype (retina (Berlie et al., 1995) ; pineal gland (O'Rourke et al., 1994) . Assuming the a 2 -adrenergic receptor mediating sedation in bovine is the D subtype, differences in the affinity cannot explain the species variability. Further studies are needed to determine whether the a 2 -adrenergic receptor subtype mediating sedation in ruminants differs from the four described a 2 -adrenergic receptors.
a 2 -Adrenergic receptors also mediate antinociception and are used in combination with opiates for the chemical management of pain. The primary site of a 2 -adrenergic receptor-mediated antinociception is the spinal cord (Yaksh, 1985) . Pharmacologically, the a 2A -adrenergic receptor has been reported to mediate this antinociceptive effect in mice (Millan, 1992) . In humans, a 2A -adrenergic receptor mRNA has been demonstrated in cervical spinal cord whereas thoracic, lumbar and sacral spinal cord contain a 2B -adrenergic receptor mRNA (Smith et al., 1995) . Further studies are necessary to determine the role of these receptor subtypes in the antinociception response produced by a 2 -adrenergic receptor agonists. In conclusion, the sedative/hypnotic agents, xylazine, detomidine and medetomidine do not show selectivity for any of the four described a 2 -adrenergic receptors determined by radioligand binding studies in tissues containing only one subtype of a 2 -adrenergic receptor.
